Lyell Immunopharma Inc.
LYEL | NASDAQ
$11.09
+$0.16 (+1.46%)
Sep 22, 2026, 10:49 AM ET · Market open
Institutional Ownership
Net InflowTotal Institutions
76
Total Ownership
54.74%
Capital Flow
+$113.09M
Shares Change
+569.02K
Ownership Distribution
Institutions (54.74%)
Others (45.26%)
Institutional Sentiment
Overall: bullishEquity Sentiment & Activity
bullishNew Positions
19
Increased Positions
43
Reduced Positions
9
Closed Positions
12
New (19)
Increased (43)
Reduced (9)
Closed (12)
Options Sentiment & Activity
bullishPut/Call Ratio
0.343
Call Flow
12,000
Put Flow
4,110
Calls (74%)
Puts (26%)
Super Investors
| Super Investor / Fund | Ownership | Portfolio Weight | Shares | Market Value | |
|---|---|---|---|---|---|
| Point72 Asset Management LP | 0.10% +85.47% | < 0.01% | 21.29K | 292.55K |
Top Shareholders
| Institution | Ownership | Portfolio Weight | Shares | Market Value | |
|---|---|---|---|---|---|
| Arch Venture Management, LLC | 14.84% -8.04% | 9.62% -26.18% | 3.25M +17.69% | 65.14M -23.30% | |
| Gsk PLC | 6.91% -21.86% | 5.06% -13.09% | 1.51M 0.00% | 30.34M -34.83% | |
| Foresite Capital Management Iv, LLC | 3.66% -21.86% | 6.77% -36.85% | 800.4K 0.00% | 16.06M -34.83% |
Pro Membership
Stop Guessing, Start Knowing.
Cut through market noise with actionable insights that actually help you make confident investment decisions. No more endless research or gut-based guessing.
Unlimited access
Unlimited access to all data and tools, giving you the edge over everyone else in the market.
Proprietary Stock Rating Score
Evaluate stocks with our proprietary rating score based on fundamentals, economic moat, and sentiment.
Top Wall Street Analyst Ratings
Follow ratings from the best analysts on Wall Street to stay ahead of market moves.
Up to 30 years financial history
We deliver premium Wall Street data with top-tier accuracy and up to 30 years of history.
Add to Watchlist
Select watchlists to add or remove LYEL